A short guide to grading images for diabetic retinopathy

In this one-on-one conversation with Paolo Lanzetta, MD, Tunde Peto, MD, PhD, gives tips and example

Learn more
Automated retinal image analysis, the way ahead

In this video, Anat Loewenstein, MD, and Srinivas Sadda, MD, share their experience in the field and

Learn more
IVEG mourns the loss of Ramin Tadayoni

The Intravitreal Expert Group joins the whole retina community in expressing deepest condolences for

Learn more
Taking care of DR in the urban slums of India

In this video, Paolo Lanzetta, MD, speaks with Sundaram Natarajan, MD, about the Aditya Jyot-study o

Learn more
The myopia epidemic: the long-term consequences

Myopia is on the rise globally, and has been more so since the COVID-19 pandemic.

Learn more
IVEG course at Floretina 2023

Learn more
Managing GA in clinical practice: new challenges, new models

With the new treatments for GA, it is important to re-think the management of patients looking at th

Learn more
The new era in the management of patients with geographic atrophy

Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr

Learn more
Euretina 2023 – Controversies and future trends in intravitreal therapies

IVEG instructional course – Euretina 2023Take-home messagesIn this video, the best of our

Learn more
IVEG Course: Controversies and Future Trends in Intravitreal Therapies

On 8 October at the Euretina 2023 congress in Amsterdam, international TLs will discuss controversie

Learn more
Home monitoring

Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r

Learn more
High-dose Aflibercept: the PHOTON and PULSAR trials

Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th

Learn more
FDA approves high-dose Eylea for the treatment of wAMD, DME and diabetic retinopathy

The U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) 8mg injection for th

Learn more
What is the current situation of ophthalmology in Ukraine?

Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.

Learn more
FDA CRL puts temporarily on hold the approval of high-dose Eylea

Regeneron announced that the FDA issued a CRL to the approval application for aflibercept 8 mg for t

Learn more
Office, ambulatory surgery room or operating theatre?

A study reviews evidence and provides recommendations for the ideal setting of intravitreal injectio

Learn more
PHOTON and PULSAR studies: an overview of the results

Professor Jean-François Korobelnik reviews the results at one year of the PHOTON and PULSAR studies

Learn more
Study revamps concerns about nonpowder toy gun as a cause of pediatric eye injuries

A study performed at the Rothschild Foundation Hospital in Paris showed that pediatric eye injuries

Learn more
The importance of diabetic eye screening

Diabetic Eye Screening campaigns have a key role in the prevention and treatment of diabetic related

Learn more
No association between RVO and mRNA COVID-19 vaccination, study shows

A retrospective, population-based study showed that there is no association between RVO and mRNA COV

Learn more
Treat and Extend – Practical guide

Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi

Learn more
Biosimilars, a new frontier?

Biosimilars entering the scene of intravitreal injections

Learn more
New treatment for Retinitis Pigmentosa shows positive results

A new optogenetic therapy is on the horizon

Learn more
Aviceda submits Investigational New Drug application for AVD-104 for geographic atrophy

Aviceda Therapeutics submitted Investigational New Drug (IND) and Fast Trac

Learn more
Durability and safety of new treatments for nAMD

Retina thought leaders give opinions on new treatments for nAMD

Learn more
First treatment for Geographic Atrophy (GA) approved by FDA

On February 17, the FDA approved SYFOVRE™ (pegcetacoplan, Apellis Pharmac

Learn more
Aflibercept 8 mg accepted by FDA for priority review for the treatment of wet AMD and DME

FDA has accepted for priority review the Biologics License Application (BLA

Learn more
A team approach to diabetes-related eye disease

To tackle diabetes-related eye diseases through a multidisciplinary team approach.

Learn more
Treat & Extend in ME secondary to CRVO

In the CENTERA study, significant functional and anatomic improvements were

Learn more
Anti-VEGF therapies for AMD: where are we now?

Where are we now with the spread of these therapies for AMD to prevent blindness?

Learn more
The Debate on Fluid Tolerance

What do the studies show? What do the experts think?

Learn more
What is on the Horizon? A Symposium on the future of ophthalmology at Euretina 2021

Home monitoring, intravitreal treatments, gene therapy, AI. The future of ophthalmology through the

Learn more
A video journey in the “new normal” of retina practices

Learn more
Euretina 2021 Virtual Congress

Learn more
Timely detection of wet AMD with remote home screening

Data from a retrospective real world study highlights low incidence of proactive treatment of nAMD

Learn more
Remote monitoring in the management of retinal disease

Learn more

About us

a panel of top-tier international vitreoretinal surgeons

The experience shared by this group of professionals is aligned with their mission to promote and provide best practice recommendations

Only modern and best equipment advanced medical technologies and innovative diagnosis and treatment methods and technology.

Learn More

 

Our organization has received a financial education grant from Bayer. Bayer has had no influence on this website content.